- Home
- TLRY vs GYRE Comparison
TLRY vs GYRE Comparison
Compare TLRY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- GYRE
- Stock Information
- Founded
- TLRY N/A
- GYRE 2002
- Country
- TLRY Canada
- GYRE United States
- Employees
- TLRY N/A
- GYRE N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- GYRE Health Care
- Exchange
- TLRY Nasdaq
- GYRE Nasdaq
- Market Cap
- TLRY 1.3B
- GYRE 1.1B
- IPO Year
- TLRY 2018
- GYRE N/A
- Fundamental
- Price
- TLRY $1.20
- GYRE $10.95
- Analyst Decision
- TLRY Hold
- GYRE
- Analyst Count
- TLRY 3
- GYRE 0
- Target Price
- TLRY $1.88
- GYRE N/A
- AVG Volume (30 Days)
- TLRY 43.8M
- GYRE 129.2K
- Earning Date
- TLRY 01-10-2025
- GYRE 11-13-2024
- Dividend Yield
- TLRY N/A
- GYRE N/A
- EPS Growth
- TLRY N/A
- GYRE N/A
- EPS
- TLRY N/A
- GYRE N/A
- Revenue
- TLRY $829,216,000.00
- GYRE $105,033,000.00
- Revenue This Year
- TLRY $16.98
- GYRE $25.32
- Revenue Next Year
- TLRY $5.96
- GYRE $12.95
- P/E Ratio
- TLRY N/A
- GYRE N/A
- Revenue Growth
- TLRY 18.38
- GYRE N/A
- 52 Week Low
- TLRY $1.14
- GYRE $8.26
- 52 Week High
- TLRY $2.97
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- TLRY 40.97
- GYRE 48.93
- Support Level
- TLRY $1.15
- GYRE $9.51
- Resistance Level
- TLRY $1.23
- GYRE $11.11
- Average True Range (ATR)
- TLRY 0.08
- GYRE 0.85
- MACD
- TLRY -0.02
- GYRE 0.04
- Stochastic Oscillator
- TLRY 13.51
- GYRE 29.33
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.